WO2015051337A3 - Methods of treating gastrointestinal disorders - Google Patents

Methods of treating gastrointestinal disorders Download PDF

Info

Publication number
WO2015051337A3
WO2015051337A3 PCT/US2014/059190 US2014059190W WO2015051337A3 WO 2015051337 A3 WO2015051337 A3 WO 2015051337A3 US 2014059190 W US2014059190 W US 2014059190W WO 2015051337 A3 WO2015051337 A3 WO 2015051337A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
gastrointestinal disorders
treating gastrointestinal
treating
decreased
Prior art date
Application number
PCT/US2014/059190
Other languages
French (fr)
Other versions
WO2015051337A2 (en
Inventor
Shanthi Srinivasan
Bindu CHANDRASEKHARAN
Malu Tansey
Original Assignee
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emory University filed Critical Emory University
Publication of WO2015051337A2 publication Critical patent/WO2015051337A2/en
Publication of WO2015051337A3 publication Critical patent/WO2015051337A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present disclosure is directed to a method of treating a gastrointestinal disorder associated with decreased enteric nerve cell survival and colonic cell motility.
PCT/US2014/059190 2013-10-04 2014-10-03 Methods of treating gastrointestinal disorders WO2015051337A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361886913P 2013-10-04 2013-10-04
US61/886,913 2013-10-04

Publications (2)

Publication Number Publication Date
WO2015051337A2 WO2015051337A2 (en) 2015-04-09
WO2015051337A3 true WO2015051337A3 (en) 2015-11-19

Family

ID=52779310

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/059190 WO2015051337A2 (en) 2013-10-04 2014-10-03 Methods of treating gastrointestinal disorders

Country Status (1)

Country Link
WO (1) WO2015051337A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10519207B2 (en) 2015-06-12 2019-12-31 Georgia State University Research Foundation, Inc. Compositions and methods for treating opioid tolerance
CN106800597B (en) * 2015-11-26 2021-07-16 上海佳文英莉生物技术有限公司 Protein for neutralizing pro-apoptosis necrosis antibody and application thereof
US20190085394A1 (en) * 2015-12-14 2019-03-21 Parkinson's Institute Refining diagnosis and treatment of complex multi-symptom neurological disorders

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060258604A1 (en) * 2005-05-10 2006-11-16 Warren Strober Compositions and methods for the treatment of inflammatory bowel disease utilizing NF-kappaB decoy polynucleotides
US20080108684A1 (en) * 2005-07-01 2008-05-08 Ajinomoto Co., Inc. Therapeutic agent for inflammatory bowel disease and tnf-alfa production inhibitor
US20080187509A1 (en) * 2000-03-02 2008-08-07 Xencor, Inc. Pharmaceutical compositions for the treatment of TNF-alpha related disorders
US20080269123A1 (en) * 2006-04-03 2008-10-30 Rong Li Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases
US20090069247A1 (en) * 2006-10-06 2009-03-12 Blake Paterson Use of tight junction antagonists to treat inflammatory bowel disease

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080187509A1 (en) * 2000-03-02 2008-08-07 Xencor, Inc. Pharmaceutical compositions for the treatment of TNF-alpha related disorders
US20060258604A1 (en) * 2005-05-10 2006-11-16 Warren Strober Compositions and methods for the treatment of inflammatory bowel disease utilizing NF-kappaB decoy polynucleotides
US20080108684A1 (en) * 2005-07-01 2008-05-08 Ajinomoto Co., Inc. Therapeutic agent for inflammatory bowel disease and tnf-alfa production inhibitor
US20080269123A1 (en) * 2006-04-03 2008-10-30 Rong Li Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases
US20090069247A1 (en) * 2006-10-06 2009-03-12 Blake Paterson Use of tight junction antagonists to treat inflammatory bowel disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHANDRASEKHARAN ET AL.: "Targeted Deletion of Neuropeptide Y (NPY) Modulates Experimental Colitis", PLOS ONE, vol. 3, no. 10, 1 October 2008 (2008-10-01), pages 1 - 11, XP002686674, ISSN: 1932-6203 *
CHANDRASEKHARAN ET AL.: "TNF alpha Inhibitors Attenuate N europe ptide Y (NPY) Expression in the Murine Enteric Nervous System", IMPLICATIONS IN INFLAMMATION AND COLONIC MOTILITY, vol. 18, December 2012 (2012-12-01), pages S93, XP055237213, Retrieved from the Internet <URL:http://journals.lww.com/ibdjournal/Citation/2012/12001/TNF8_Inhibitors_Attenuate_Neuropeptide_Y_NPY_.229.aspx> [retrieved on 20150225] *

Also Published As

Publication number Publication date
WO2015051337A2 (en) 2015-04-09

Similar Documents

Publication Publication Date Title
SG11202003201QA (en) Methods of producing modified natural killer cells and methods of use
ZA201604730B (en) Lignin nanoparticle dispersions and methods for producing and using the same
IL285258A (en) Retinal ganglion cells and progenitors thereof
EP2983657A4 (en) Treatment of gastrointestinal and other disorders
TWI559966B (en) Method and device of community interaction with toy as the center
EP2968298A4 (en) Deuterium-enriched 2,4-thiazolidinediones and methods of treatment
HK1245132A1 (en) Methods to improve cell therapy
IL252000B (en) Novel uhmwpe fiber and method to produce
HUE041716T2 (en) Carbonization method and carbon fiber production method
MX2020002852A (en) Improved treatment of atopic dermatitis with tradipitant.
SI3022274T1 (en) Method for producing flame-retardant copolyamides, the polyamide yarns that can be obtained according to the method, and use of said polyamide yarns
EP3094328A4 (en) Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
EP3458147A4 (en) Systems methods and devices for closed-loop stimulation to enhance stroke recovery
EP2976094A4 (en) Methods of treating metabolic disorders
GB2547123B (en) LED vertical chip structure with special coarsening morphology and preparation method therefor
WO2015051337A3 (en) Methods of treating gastrointestinal disorders
HK1243648A1 (en) Methods to enhance nerve regeneration utilizing neural stem cells and il12p40
WO2015089503A3 (en) Treating brain disorders and biomarkers related thereto
AU361187S (en) A physiotherapy apparatus
EP3642360C0 (en) Methods relating to the capture of ca-ix positive exosomes
EP3055678A4 (en) Challenge sets and methods of making and using the same
EP2968609A4 (en) Vectors and methods to treat ischemia
IL274527B2 (en) Process to produce nanoparticles
ZA201701516B (en) Efi ignition module and method of production
PL3151995T3 (en) Method of fastening conductors to an electrodes-arrangement in the production of an energy storage cell

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14850153

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14850153

Country of ref document: EP

Kind code of ref document: A2